Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Can-Fite BioPharma Ltd (Can-Fite), is a clinical stage drug development company that strives to develop small-molecule drugs for the treatment of cancer and inflammatory diseases. The company’s pipeline products which are in phase II and III clinical development stage includes CF101, for rheumatoid arthritis and psoriasis, CF102, for hepatocellular carcinoma and CF602, for erectile dysfunction. Can-Fite develops its products by harnessing its technology platform which is based on the Gi protein associated A3 adenosine receptor (A3AR). The company works in collaboration with pharmaceutical and biotechnology companies to develop its product portfolio. It has operations in Israel and the US. Can-Fite is headquartered in Petah Tikva, Israel.
Headquarters
Israel
Address
26 Ben Gurion Street, Ramat Gan, 5257346
Website
www.canfite.com
Telephone
972 3 9241114
No of Employees
5
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CANF (TLV)
Revenue (2022)
$743,000
-8.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
25%
(2022 vs 2021)
Market Cap*
$10.8M
Net Profit Margin (2022)
XYZ
18.2%
(2022 vs 2021)
* As of and is in US$
Can-Fite BioPharma Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| CF602 - Erectile Dysfunction |
| Piclidenoson (CF101) - Rheumatoid Arthritis and Psoriasis |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In August, the company signed agreement with Fondazione Telethon to develop its lead drug candidate, Piclidenoson, for the treatment of Lowe Syndrome. |
| 2020 | Contracts/Agreements | In March, the company entered into a collaborative research agreement with the Lewis Katz School of Medicine to explore anti-viral activity of Piclidenoson on coronaviruses viral load in a mammalian cell model system. |
| 2019 | Contracts/Agreements | In September, the company signed an agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. |
Competitor Comparison
| Key Parameters | Can-Fite BioPharma Ltd | Amgen Inc | BioLineRx Ltd | Aposense Ltd | Chemomab Therapeutics Ltd |
|---|---|---|---|---|---|
| Headquarters | Israel | United States of America | Israel | Israel | Israel |
| City | Ramat Gan | Thousand Oaks | Modiin | Petach-Tikva | Tel Aviv-Yafo |
| State/Province | - | California | - | Petah Tikva | - |
| No. of Employees | 5 | 26,700 | 79 | 29 | 20 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ilan Cohn | Director; Chairman | Executive Board | 2020 | 67 |
| Pnina Fishman | Chief Executive Officer; Director | Executive Board | 2005 | 74 |
| Michael Silverman | Director - Medical | Senior Management | - | - |
| Zivit Harpaz | Director - Regulatory and Clinical Operations | Senior Management | - | - |
| William D. Kerns | Vice President - Drug Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer